Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
Jason D. Lickliter, Kenneth Lawrence, John P. O’Donnell, Robin Isaacs
Abstract
Durlobactam (DUR; also known as ETX2514) is a novel β-lactamase inhibitor with broad activity against Ambler class A, C, and D β-lactamases. Addition of DUR to sulbactam (SUL) in vitro restores SUL activity against clinical isolates of Acinetobacter baumannii . The safety and pharmacokinetics (PK) of DUR alone and with SUL and/or imipenem-cilastatin (IMI-CIL) were evaluated in healthy subjects. This was a randomized, placebo-controlled study. In part A, subjects, including a cohort of elderly subjects (which received DUR at 1 g), received single ascending doses of DUR ranging from 0.
Topics & Concepts
PharmacokineticsDrugPharmacologyMedicineBeta-Lactamase InhibitorsDrug-drug interactionIntravenous drugDrug interactionAntibioticsChemistryImmunologyVirusViral diseaseBiochemistryAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyAntimicrobial Resistance in Staphylococcus